Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 3

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 3
---
ITEM 3. KEY INFORMATION

A.   [Reserved]
---------------

B.   Capitalization and Indebtedness
------------------------------------

Not applicable.

C.   Reasons for the Offer and Use of Proceeds
----------------------------------------------

Not applicable.

D.   Risk Factors
-----------------

Investing in our securities involves a high degree of risk and uncertainty. You should carefully consider the risks and uncertainties described below before investing in our securities. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be harmed. In that case, the daily price of our securities could decline, and you could lose all or part of your investment. These risk factors include:

Risks Related to Our Financial Condition 

●                                                                      We                                                                  
    have a history of operating losses and will continue to incur losses whilst conducting clinical trials. However, we also have a history
      of successfully raising funds via equity capital raisings, and as a result, we have a strong cash position for the fiscal year ended 
     June 30, 2025. The continuing viability of the Group is subject to its ability to raise additional capital to finance the continuation
     of its planned research and development programs, maintaining implemented cost containment and deferment strategies, and successfully 
     commercializing its initiatives. The Group successfully raised new equity funding during the 2025 financial year to enable progression
                               of its planned research and development programs for at least the next 12 months.                           
-------------------------------------------------------------------------------------------------------------------------------------------

●                                                                      We                                                                   
    will still need additional funding to operate our business in the future; such funding may not be available or, if it is available, such
                                     financing is likely to substantially dilute our existing shareholders.                                 
--------------------------------------------------------------------------------------------------------------------------------------------
Risks Related to Our Business

●                                                            We                                                        
    are a development stage company engaged in the development of pharmaceutical products and our success is uncertain.
-----------------------------------------------------------------------------------------------------------------------

●                                          We rely on research institutions to conduct our clinical                                       
    trials and we may not be able to secure and maintain research institutions to conduct our future trials. The institutions that we work
    with have their own limits and procedures that will influence or limit our ability to conduct research and development and the conduct
                                                             of clinical trials.                                                          
------------------------------------------------------------------------------------------------------------------------------------------

●                             We                         
    are faced with uncertainties related to our research.
---------------------------------------------------------

●                                                  Clinical                                               
    trials as they